NCT05644626 2023-11-29
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
BeiGene
Phase 1 Withdrawn
Clinical Trials
4 trialsNCT05791097 2023-07-24
AdvanTIG-306
Novartis
Phase 3 Withdrawn
NCT05809895 2023-07-24
AdvanTIG-211
Novartis
Phase 2 Withdrawn
NCT05564338 2023-06-07
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
BeiGene
Phase 3 Withdrawn